SOUTH SAN FRANCISCO, Calif. , March 31, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that updates on several of its preclinical programs are
SOUTH SAN FRANCISCO, Calif. , March 30, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today provided a corporate update and announced 2016 financial
One patient of four (25%) achieved a complete remission No dose-limiting toxicities observed and study is progressing into the fourth dose cohort SOUTH SAN FRANCISCO, Calif. , March 15, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular
In one study most animals receiving the combination of CA4P and anti-CTLA4 antibody were tumor free at completion Three additional studies provide evidence that CA4P may enhance anti-CTLA4, anti-PD1, and anti-PD-L1 antibody activity SOUTH SAN FRANCISCO, Calif. , Feb.
SOUTH SAN FRANCISCO, Calif. , Feb. 07, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that it will present a company overview at the 19 th
- Data Shows Additional Evidence of CA4P Activity - - Investigator-sponsored Study Initiating, Based on OX4218 Results - SOUTH SAN FRANCISCO, Calif. , Jan. 20, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs)
SOUTH SAN FRANCISCO, Calif. , Dec. 07, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that shares of its common stock will be eligible for
- Completed enrollment in the two lowest dose cohorts, third cohort now in progress - - Patients had on average failed 4 prior therapies - - Across the first two cohorts, 20% of patients achieved a complete remission - SOUTH SAN FRANCISCO, Calif. , Dec.
SOUTH SAN FRANCISCO, Calif. , Nov. 14, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today provided a corporate update and reported financial results for
